Abstract:D.J. Paustenbach et al. (1986, Fundam. Appl. Toxicol. 6, 484-497) have described the pharmacokinetics of inhaled, radiolabeled carbon tetrachloride (14CCl4) in male Sprague-Dawley rats exposed for 8 or 11.5 hr/day for 1- or 2-week periods. These studies provided time-course information for exhaled 14CCl4, the exhaled 14CO2 metabolite, and 14C radioactivity eliminated in the feces and urine. A physiologically based pharmacokinetic (PB-PK) model which incorporated partition characteristics of CCl4 (blood:air and tissue:blood partition coefficients), anatomical and physiological parameters of the test species (body weight, organ weights, ventilation rates, blood flows, etc.), and biochemical constants (Vmax and Km) for CCl4 metabolism was developed to describe these results. The PB-PK model accurately predicted the behavior of CCl4 and its metabolites, both the exhaled CCl4 and 14CO2 and the elimination of radioactivity in urine and feces. The metabolism of CCl4, determined by gas uptake studies, was adequately described by a single saturable pathway. Metabolites were partitioned in the model to three compartments; the amounts to be excreted in the breath (as 14CO2), urine, and feces. Of total CCl4 metabolism, 6.5, 9.5, and 84.0% were formed via the degradative pathways leading to CO2, urinary, and fecal metabolites, respectively. The simplest kinetic explanation of the metabolite time course is that 4% of the initially metabolized CCl4 is directly converted to CO2 (probably via a chloroform intermediate) and the remainder of metabolized CCl4 binds to biological substrates. These adducts appear to be slowly degraded with an average half-life of 24 hr. The breakdown products subsequently appear in the feces and urine (the rate constant for elimination by these two routes is similar) and a small portion is converted all the way to CO2. The PB-PK model successfully described the elimination by all four routes for all four exposure scenarios using a single set of parameters. Vmax and Km were, respectively, 0.65 mg/kg/hr and 0.25 mg/liter. There was no evidence for loss of Vmax with repeated exposure, as would be expected if there was enzyme destruction at these concentrations of CCl4. The model was scaled-up to predict the expected behavior of parent CCl4 in monkeys and humans and the resulting simulations compared very favorably with data collected by McCollister et al. (1951) and Stewart et al. (1961). On the basis of this model and the published data on the rat at 100 ppm about 60% of the inhaled CCl4 is metabolized and the resulting blood levels are already in excess of saturation for the metabolizing enzymes.(ABSTRACT TRUNCATED AT 250 WORDS)

Using available in vitro metabolite identification and time course kinetics for β-chloroprene and its metabolite, (1-chloroethenyl) oxirane, to include reactive oxidative metabolites and glutathione depletion in a PBPK model for β-chloroprene

Development of Physiologically Based Toxicokinetic Models for 3-Monochloropropane-1,2-diol and Glycidol.

Integration of Metabolomics and Transcriptomics Reveals Short-Chain Chlorinated Paraffin-Induced Hepatotoxicity in Male Sprague-Dawley Rat.

Physiologically Based Pharmacokinetic Modeling for Chlorinated Paraffins in Rats and Humans: Importance of Biliary Excretion.

Chlorpyrifos PBPK/PD model for multiple routes of exposure

Physiologically Based Pharmacokinetic (pbpk) Modeling of Interstrain Variability in Trichloroethylene Metabolism in the Mouse

Modeling PAH Mixture Interactions in a Human In Vitro Organotypic Respiratory Model

In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From β‐Isomer Propylene Glycol Methyl Ether

Cell line-based in vitro models of normal and chronic bronchitis-like airway mucosa to study the toxic potential of aerosolized palladium nanoparticles

A physiologically based toxicokinetic model for microplastics and nanoplastics in mice after oral exposure and its implications for human dietary exposure assessment

Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations

New Approach Methodology for Assessing Inhalation Risks of a Contact Respiratory Cytotoxicant: Computational Fluid Dynamics-Based Aerosol Dosimetry Modeling for Cross-Species and In Vitro Comparisons

Physiologically Based Toxicokinetic Modelling of Tri(2-chloroethyl) Phosphate (TCEP) in Mice Accounting for Multiple Exposure Routes

In Vitro Metabolism and p53 Activation of Genotoxic Chemicals: Abiotic CYP Enzyme vs Liver Microsomes

A physiologically based pharmacokinetic model for inhaled carbon tetrachloride

The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment

Differential effects of benzo[a]pyrene exposure on glutathione and purine metabolism in keratinocytes: Dose‐dependent and UV co‐exposure effects

Metabolically Competent Human Skin Models: Activation and Genotoxicity of Benzo[a]pyrene

Considerations for the optimization of in vitro models of chloropicrin toxicity

Induction of Glutathione S-Transferase Pi As A Bioassay for the Evaluation of Potency of Inhibitors of Benzo(A)Pyrene-Induced Cancer in A Murine Model

Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing